The molecular genetics of familial venous thrombosis

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 479-503

  Simioni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Clotting inhibitors; Factor V (Leiden); Familial thrombophilia; Inherited coagulation defects; Medical genetics; Mild hyperhomocysteinaemia; Prothrombin (G20210A)

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; FIBRINOGEN; HEPARIN COFACTOR II; HOMOCYSTEINE; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN;

DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE DELETION; GENE INSERTION; GENETIC PREDISPOSITION; GENOTYPE; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; MOLECULAR GENETICS; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; RNA PROCESSING; STOP CODON; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0033510180     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0037     Document Type: Article

References (177)

1. Olds R J, Lane D A, Mille B. Antithrombin the major inhibitor of thrombin. Seminars in Thrombosis and Haemostasis. 20:1995;353-372.
2. Gettins P, Patston P A, Schapira M. The role of conformational change in serpin structure and function. Bioessays. 15:1993;461-467.
3. Lawrence D A, Ginsburg D, Day D E. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. Journal of Biological Chemistry. 270:1995;25309-25310.
4. Bjork I, Olson S T, Shore J D. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and the clotting proteinases. Lane D A, Lindahl U. Heparin: Chemical and Biological Properties, Clinical Applications. 1989;229-255 Edward Arnold, London.
5. Olson S T, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. Journal of Biological Chemistry. 266:1991;6353-6364.
6. Casu B, Oreste P, Torri G. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III binding sequence. Biochemical Journal. 80:1981;599-609.
7. Atha D H, Stephens A W, Rosenberg R D. Evaluation of critical groups required for binding of heparin to antithrombin. Proceedings of the National Academy of Sciences of the USA. 81:1984;1030-1034.
8. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis and Diathesis Haemorrhagica. 13:1965;516-530.
9. Blajchman M A, Austin R C, Fernandez-Rachubinsky F, Sheffield W P. Molecular basis of inherited human antithrombin deficiency. Blood. 80:1992;2159-2171.
10. Lane D A, Olds R J, Thein S L. Antithrombin and its deficiency states. Blood Coagulation and Fibrinolysis. 3:1992;315-341.
11. Beresford C H. Antithrombin III deficiency. Blood Reviews. 2:1988;239-250.
12. Tait R C, Walker I D, Perry D J. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thrombosis and Haemostasis. 65:1991;839.
13. Gladson C L, Scharrer I, Hach V. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thrombosis and Haemostasis. 59:1988;18-22.
14. Heijboer H, Brandjes D PM, Buller H R. Deficiencies of coagulation inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. New England Journal of Medicine. 323:1990;1512-1516.
15. Lane D A, Olds R J, Boisclair M. Antithrombin III mutation database: first update. Thrombosis and Haemostasis. 70:1993;361-369.
16. Martinelli I, Mannucci P M, De Stefano V. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 92:1998;2353-2358.
17. Simioni P, Sanson B J, Prandoni P. Incidence of venous thromboembolism in families with inherited thrombophilia. Thrombosis and Haemostasis. 81:1999;198-202.
18. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thrombosis and Haemostasis. 58:1987;1094.
19. van Boven H H, Reitsma P H, Rosendaal F R. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thrombosis and Haemostasis. 75:1996;417-421.
20. Lane D A, Bayston T, Olds R J. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. 77:1997;197-211.
21. Bayston T A, Lane D A. Antithrombin: molecular basis of deficiency. Thrombosis and Haemostasis. 78:1997;339-343.
22. Emmerich J, Vidaud D, Alhenc-Gelas M. Three novel mutations of antithrombin inducing high-molecular-mass compounds. Arteriosclerosis and Thrombosis. 14:1994;1958-1965.
23. Berg L P, Grundy C B, Thomas F. De novo splice site mutation in the antithrombin III (AT3) gene causing recurrent venous thrombosis: demonstration of exon skipping by ectopic transcript analysis. Genomics. 13:1992;1359-1361.
24. Millar D S, Lopez A, White D. Screening for mutations in the antithrombin III gene causing recurrent venous thrombosis by single-strand conformation polymorphism analysis. Human Mutation. 2:1993;324-326.
25. Gandrille S, Vidaud D, Emmerich J. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon in exon IIIa and a frameshift in exon VI. British Journal of Haematology. 78:1991;414-420.
26. Olds R J, Lane D A, Ireland H. A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop). Thrombosis Research. 64:1991;621-625.
27. van Boven H H, Olds R J, Thein S L. Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood. 84:1994;4209-4213.
28. Chowdhury V, Olds R J, Lane D A. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. British Journal of Haematology. 84:1993;656-661.
29. Emmerich J, Chadeuf G, Alhenc-Gelas M. Molecular basis of antithrombin type I deficiency: the first large in-frame deletion and two novel mutations in exon 6. Thrombosis and Haemostasis. 72:1994;534-539.
30. Perry D J, Carrell R W. CpG dinucleotides are 'hotspots' for mutation in the antithrombin III gene. Twelve variants identified using the polymerase chain reaction. Molecular Biology and Medicine. 6:1989;239-243.
31. Winter J H, Bennett B, Watt J L. Confirmation of linkage between antithrombin III and Duffy blood group and assignment of AT3 to 1q22 lead to q25. Annals of Human Genetics. 46:1982;29-34.
32. Olds R J, Lane D A, Chowdhury V. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 32:1993;4216-4224.
33. Ireland H, Lane D A, Thompson E. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. British Journal of Haematology. 79:1991;70-74.
34. Erdjument H, Lane D A, Ireland H. Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin 'Northwick Park'. Journal of Biological Chemistry. 262:1987;13381-13384.
35. Olson S T, Sheffer R, Stephens A W, Hirs C HW. Molecular basis of the reduced activity of antithrombin Denver with thrombin and factor Xa. Role of the P1′ residue. Thrombosis and Haemostasis. 65:1991;670.
36. Bruce D, Perry D J, Borg J Y. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp). Journal of Clinical Investigation. 94:1994;2265-2274.
37. Olds R J, Lane D A, Boisclair M. Antithrombin Budapest 3. An antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Letters. 300:1992;241-246.
38. Brennan S O, Borg J Y, George P M. New carbohydrate site in mutant antithrombin (7 Ile-Asn) with decreased heparin affinity. FEBS Letters. 237:1988;118-122.
39. Watton J, Longstaff C, Lane D A, Barrowcliffe T W. Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III. Biochemistry. 32:1993;7286-7293.
40. Lane D A, Olds R J, Conard J. Pleiotropic effects of antithrombin strand 1C substitution mutations. Journal of Clinical Investigation. 90:1992;2422-2433.
41. Sheffield W P, Castillo J E, Blajchman M A. Intracellular events determine the fate of antithrombin Utah. Blood. 86:1995;3461-3467.
42. Walker F J, Fay P J. Regulation of blood coagulation by the protein C system. FASEB Journal. 6:1992;2561-2567.
43. Dahlback B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. Bloom A L, Forbes C D, Thomas D P, Tuddenham E GD. Haemostasis and Thrombosis. 1994;671-679 Churchill Livingstone, Edinburgh.
44. Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thrombosis Research. 77:1995;1-43.
45. Koeleman B P, Reitsma P H, Allaart C F, Bertina R M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 84:1994;1031-1035.
46. Koeleman B P, Reitsma P H, Bertina R M. Familial thrombophilia: a complex genetic disorder. Seminars in Hematology. 34:1997;256-264.
47. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. Journal of Biological Chemistry. 251:1976;355-363.
48. Foster D C, Rudinski M S, Schach B G. Propeptide of human protein C is necessary for gamma-carboxylation. Biochemistry. 26:1987;7003-7011.
49. Foster D C, Yoshitake S, Davie E W. The nucleotide sequence of the gene for human protein C. Proceedings of the National Academy of Sciences of the USA. 82:1985;4673-4677.
50. Foster D C, Davie E W. Characterisation of a cDNA coding for human protein C. Proceedings of the National Academy of Sciences of the USA. 81:1984;4766-4770.
51. Beckmann R J, Schmidt R J, Santerre R F. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Research. 13:1985;5233-5247.
52. Plutzky J, Hoskins J A, Long G L, Crabtree G R. Evolution and organization of the human protein C gene. Proceedings of the National Academy of Sciences of the USA. 83:1986;546-550.
53. Rocchi M, Roncuzzi L, Santamaria R. Mapping through somatic cell hybrids and cDNA probes of protein C to chromosome 2, factor X to chromosome 13, and alpha 1-acid glycoprotein to chromosome 9. Human Genetics. 74:1986;30-33.
54. Patracchini P, Aiello V, Palazzi P. Sublocalization of the human protein C gene on chromosome 2q13-q14. Human Genetics. 81:1989;191-192.
55. Dolan G, Neal K, Cooper P. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. British Journal of Haematology. 86:1994;798-803.
56. Henkens C M, Bom V J, van der Schaaf W. Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thrombosis and Haemostasis. 74:1995;1271-1275.
57. Rodeghiero F, Tosetto A. The VITA project: population-based distributions of protein C, antithrombin III, heparin co-factor II and plasminogen-relationship with physiological variables and establishment of reference ranges. Thrombosis and Haemostasis. 76:1996;226-233.
58. Griffin J H, Evatt B, Zimmerman T S. Deficiency of protein C in congenital thrombotic disease. Journal of Clinical Investigation. 68:1981;1370-1373.
59. Broekmans A W, Conard J. Hereditary protein C deficiency. Bertina R M. Protein C and Related Proteins. 1988;160-187 Churchill Livingstone, Edinburgh.
60. Allaart C F, Poort S R, Rosendaal F R. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 341:1993;134-138.
61. Pabinger I, Allaart C F, Hermans J. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group. Thrombosis and Haemostasis. 68:1992;470-474.
62. Seligsohn U, Berger A, Abend M. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. New England Journal of Medicine. 310:1984;559-562.
63. Manco-Johnson M J, Marlar R A, Jacobson L J. Severe protein C deficiency in newborn infants. Journal of Pediatrics. 113:1988;359-363.
64. Marlar R A, Montgomery R R, Broekmans A W. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. Journal of Pediatrics. 114:1989;528-534.
65. Dreyfus M, Magny J F, Bridey F. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. New England Journal of Medicine. 325:1991;1565-1568.
66. Dreyfus M, Masterson M, David M. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Seminars in Thrombosis and Hemostasis. 21:1995;371-381.
67. Sanz-Rodriguez C, Gil-Fernandez J J, Zapater P. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thrombosis and Haemostasis. 81:1999;887-890.
68. De Stefano V, Mastrangelo S, Schwarz H P. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thrombosis and Haemostasis. 70:1993;247-249.
69. Vasse M, Borg J Y, Monconduit M. Protein C: Rouen, a new hereditary protein C abnormality with low anticoagulant but normal amidolytic activities. Thrombosis Research. 56:1989;387-398.
70. Mimuro J, Muramatsu S, Kaneko M. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG→GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency. International Journal of Hematology. 57:1993;9-14.
71. + +. British Journal of Haematology. 85:1993;521-527.
72. Gandrille S, Alhenc-Gelas M, Gaussem P. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood. 82:1993;159-168.
73. Wojcik E G, Simioni P, van den Berg M. Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin. Thrombosis and Haemostasis. 75:1996;70-75.
74. Reitsma P H, Bernardi F, Doig R G. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thrombosis and Haemostasis. 73:1995;876-889.
75. Miyata T, Zheng Y Z, Sakata T, Kato H. Protein C Osaka 10 with aberrant propeptide processing: loss of anticoagulant activity due to an amino acid substitution in the protein C precursor. Thrombosis and Haemostasis. 74:1995;1003-1008.
76. Lind B, Johnsen A H, Thorsen S. Naturally occurring Arg(-1) to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood. 89:1997;2807-2816.
77. Diuguid D L, Rabiet M J, Furie B C. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proceedings of the National Academy of Sciences of the USA. 83:1986;5803-5807.
78. Wojcik E G, van den Berg M, van der Linden I K. Factor IX Zutphen: a Cys18→Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation. Biochemical Journal. 311:1995;753-759.
79. Lu D, Bovill E G, Long G L. Molecular mechanism for familial protein C deficiency and thrombosis in protein CVermont (Glu20→Ala and Val34→Met). Journal of Biological Chemistry. 269:1994;29032-29038.
80. Lu D, Kalafatis M, Mann K G, Long G L. Loss of membrane-dependent factor Va cleavage: a mechanistic interpretation of the pathology of protein CVermont. Blood. 84:1994;687-690.
81. Nishioka J, Ido M, Hayashi T, Suzuki K. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va. Thrombosis and Haemostasis. 75:1996;275-282.
82. Fisher C L, Greengard J S, Griffin J H. Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Science. 3:1994;588-599.
83. Rezaie A R, Esmon C T. Proline at the P2 position in protein C is important for calcium-mediated regulation of protein C activation and secretion. Blood. 83:1994;2526-2531.
84. Katsumi A, Senda T, Yamashita Y. Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Blood. 87:1996;4164-4175.
85. Wacey A I, Pemberton S, Cooper D N. A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. British Journal of Haematology. 84:1993;290-300.
86. Greengard J S, Fisher C L, Villoutreix B, Griffin J H. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. Proteins. 18:1994;367-380.
87. Simioni P, Kalafatis M, Millar D S. Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. Blood. 88:1996;2101-2108.
88. Spek C A, Greengard J S, Griffin J H. Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Journal of Biological Chemistry. 270:1995;24216-24221.
89. Miao C H, Ho W T, Greenberg D L, Davie E W. Transcriptional regulation of the gene coding for human protein C. Journal of Biological Chemistry. 271:1996;9587-9594.
90. Berg L P, Scopes D A, Alhaq A. Disruption of a binding site for hepatocyte nuclear factor 1 in the protein C gene promoter is associated with hereditary thrombophilia. Human Molecular Genetics. 3:1994;2147-2152.
91. Miyata T, Sakata T, Zheng Y Z. Genetic characterization of protein C deficiency in Japanese subjects using a rapid and nonradioactive method for single-stand conformational polymorphism analysis and a model building. Thrombosis and Haemostasis. 76:1996;302-311.
92. Reitsma P H, Poort S R, Allaart C F. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood. 78:1991;890-894.
93. Krawczak M, Cooper D N. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Human Genetics. 86:1991;425-441.
94. Soria J M, Berg L P, Fontcuberta J. Ectopic transcript analysis indicates that allelic exclusion is an important cause of type I protein C deficiency in patients with nonsense and frameshift mutations in the PROC gene. Thrombosis and Haemostasis. 75:1996;870-876.
95. Fair D S, Marlar R A, Levin E G. Human endothelial cells synthesize protein S. Blood. 67:1986;1168-1171.
96. Schwarz H P, Heeb M J, Wencel-Drake J D, Griffin J H. Identification and quantitation of protein S in human platelets. Blood. 66:1985;1452-1455.
97. Walker F J. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. Journal of Biological Chemistry. 256:1981;11128-11131.
98. Kalafatis M, Rand M D, Mann K G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. Journal of Biological Chemistry. 269:1994;31869-31880.
99. Rosing J, Hoekema L, Nicolaes G A. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. Journal of Biological Chemistry. 270:1995;27852-27858.
100. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. Journal of Biological Chemistry. 269:1994;18735-18738.
101. Varadi K, Rosing J, Tans G. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thrombosis and Haemostasis. 76:1996;208-214.
102. Chang G T, Aaldering L, Hackeng T M. Construction and characterization of thrombin-resistant variants of recombinant human protein S. Thrombosis and Haemostasis. 72:1994;693-697.
103. Hillarp A, Dahlback B. Novel subunit in C4b-binding protein required for protein S binding. Journal of Biological Chemistry. 263:1988;12759-12764.
104. Chang G T, Maas B H, Ploos van Amstel H K. Studies of the interaction between human protein S and human C4b-binding protein using deletion variants of recombinant human protein S. Thrombosis and Haemostasis. 71:1994;461-467.
105. Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. New England Journal of Medicine. 311:1984;1525-1528.
106. Schwarz H P, Fischer M, Hopmeier P. Plasma protein S deficiency in familial thrombotic disease. Blood. 64:1984;1297-1300.
107. Gandrille S, Borgel D, Ireland H. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. 77:1997;1201-1214.
108. Faioni E M, Boyer-Neumann C, Franchi F. Another protein S functional assay is sensitive to resistance to activated protein C. Thrombosis and Haemostasis. 72:1994;648.
109. Simioni P, Gavasso S, Luni S. A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. Blood Coagulation and Fibrinolysis. 6:1995;286-287.
110. Faioni E M, Franchi F, Asti D. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thrombosis and Haemostasis. 70:1993;1067-1071.
111. Schmidel D K, Tatro A V, Phelps L G. Organization of the human protein S genes. Biochemistry. 29:1990;7845-7852.
112. Ploos van Amstel H K, Reitsma P H, van der Logt C P, Bertina R M. Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. Biochemistry. 29:1990;7853-7871.
113. Edenbrandt C M, Lundwall A, Wydro R, Stenflo J. Molecular analysis of the gene for vitamin K dependent protein S and its pseudogene. Cloning and partial gene organization. Biochemistry. 29:1990;7861-7868.
114. Cooper D N, Krawczak M. Protein S and protein S deficiency. Cooper D N, Krawczak M. Venous Thrombosis: from Genes to Clinical Medicine. 1997;97-117 Bios Scientific Publishers, Oxford.
115. Cooper D N, Krawczak M. Human gene mutation. Cooper D N, Krawczak M. Human Gene Mutation. 1993;163-230 Bios Scientific Publishers, Oxford.
116. Schmidel D K, Nelson R M, Broxson E H Jr. A 5·3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families. Blood. 77:1991;551-559.
117. Ploos van Amstel H K, Huisman M V, Reitsma P H. Partial protein S gene deletion in a family with hereditary thrombophilia. Blood. 73:1989;479-483.
118. Borgel D, Duchemin J, Alhenc-Gelas M. Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. Journal of Laboratory and Clinical Medicine. 128:1996;218-227.
119. Bertina R M, Ploos van Amstel H K, van Wijngaarden A. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood. 76:1990;538-548.
120. Duchemin J, Gandrille S, Borgel D. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Blood. 86:1995;3436-3443.
121. Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 85:1995;3524-3531.
122. Gandrille S, Borgel D, Eschwege-Gufflet V. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood. 85:1995;130-138.
123. Kalafatis M, Krishnaswamy S, Rand M D, Mann K G. Factor V. Methods in Enzymology. 222:1993;224-236.
124. Kane W H, Davie E W. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 71:1988;539-555.
125. Mann K G, Jenny R J, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annual Review of Biochemistry. 57:1988;915-956.
126. Jenny R J, Mann K G. Factor V: a prototype pro-cofactor for vitamin K-dependent enzyme complexes in blood clotting. Baillières Clinical Haematology. 2:1989;919-944.
127. Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
128. Kalafatis M, Bertina R M, Rand M D, Mann K G. Characterization of the molecular defect in factor VR506Q. Journal of Biological Chemistry. 270:1995;4053-4057.
129. Hayward C P, Furmaniak-Kazmierczak E, Cieutat A M. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. Journal of Biological Chemistry. 270:1995;19217-19224.
130. Cripe L D, Moore K D, Kane W H. Structure of the gene for human coagulation factor V. Biochemistry. 31:1992;3777-3785.
131. Tuddenham E GD, Cooper D N. The Molecular Genetics of Haemostasis and its Inherited Disorders. 1994;Oxford University Press, Oxford.
132. Manotti C, Quintavalla R, Pini M. Thromboembolic manifestations and congenital factor V deficiency: a family study. Haemostasis. 19:1989;331-334.
133. Simioni P, Scudeller A, Radossi P. 'Pseudo homozygous' activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thrombosis and Haemostasis. 75:1996;422-426.
134. Guasch J F, Lensen R P, Bertina R M. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is 'pseudo homozygous' for activated protein C resistance. Thrombosis and Haemostasis. 77:1997;252-257.
135. Delahousse B, Iochmann S, Pouplard C. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays. Blood Coagulation and Fibrinolysis. 8:1997;503-509.
136. Castaman G, Tosetto A, Ruggeri M, Rodeghiero F. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. British Journal of Haematology. 106:1999;232-236.
137. Castoldi E, Kalafatis M, Lunghi B. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thrombosis and Haemostasis. 80:1998;403-406.
138. Lunghi B, Castoldi E, Mingozzi F. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood. 92:1998;1463-1464.
139. Bernardi F, Faioni E M, Castoldi E. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 90:1997;1552-1557.
140. Zehnder J L, Hiraki D D, Jones C D. Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford. Thrombosis and Haemostasis. 82:1999;1097-1099.
141. Kalafatis M, Bernardi F, Simioni P. Phenotype and genotype expression in pseudohomozygous factor V Leiden: the need for phenotype analysis. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;336-342.
142. Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the USA. 90:1993;1004-1008.
143. Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. New England Journal of Medicine. 330:1994;517-522.
144. Zoller B, Svensson P J, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of Clinical Investigation. 94:1994;2521-2524.
145. Koster T, Rosendaal F R, de Ronde H. Venous thrombosis due to poor anticoagulant responses to activated protein C: Leiden Thrombophilia Study. Lancet. 342:1993;1503-1506.
146. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 343:1994;1536-1538.
147. Greengard J S, Eichinger S, Griffin J H, Bauer K A. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. New England Journal of Medicine. 331:1994;1559-1562.
148. Bajzar L, Kalafatis M, Simioni P, Tracy P B. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. Journal of Biological Chemistry. 271:1996;22949-22952.
149. Rees D C, Cox M, Clegg J B. World distribution of factor VLeiden. Lancet. 346:1995;1133-1134.
150. Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden. Blood. 85:1995;1504-1508.
151. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thrombosis and Haemostasis. 78:1997;297-301.
152. Brenner B, Zivelin A, Lanir N. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood. 88:1996;877-880.
153. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523.
154. Koeleman B P, van Rumpt D, Hamulyak K. Factor VLeiden: an additional risk factor for thrombosis in protein S deficient families? Thrombosis and Haemostasis. 74:1995;580-583.
155. Bertina R M. The prothrombin 20210 G to A variation and thrombosis. Current Opinion in Hematology. 5:1998;339-342.
156. Williamson D, Brown K, Luddington R. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 91:1998;1140-1144.
157. Simioni P, Kalafatis M, Manfrin D. Factor V variants, activated protein C resistance and venous thromboembolism. Blood Coagulation and Fibrinolysis. 9:1998;661-662.
158. Chan W P, Lee C K, Kwong Y L. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 91:1998;1135-1139.
159. de Visser M C, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 93:1999;1271-1276.
160. Kiechl S, Muigg A, Santer P. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation. 99:1999;614-619.
161. Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
162. Makris M, Preston F E, Beauchamp N J. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thrombosis and Haemostasis. 78:1997;1426-1429.
163. Rosendaal F R, Doggen C J, Zivelin A. Geographic distribution of the 20210 G to A prothrombin variant. Thrombosis and Haemostasis. 79:1998;706-708.
164. Koster T, Blann A D, Briet E. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 345:1995;152-155.
165. O'Donnell J, Tuddenham E G, Manning R. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thrombosis and Haemostasis. 77:1997;825-828.
166. Roelse J C, Koopman M M, Buller H R. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. British Journal of Haematology. 92:1996;740-743.
167. Rees M M, Rodgers G M. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thrombosis Research. 71:1993;337-359.
168. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thrombosis and Haemostasis. 81:1999;165-176.
169. Guba S C, Fonseca V, Fink L M. Hyperhomocysteinemia and thrombosis. Seminars in Thrombosis and Hemostasis. 25:1999;291-309.
170. Mudd S H, Levy H L, Skovby F. Disorders of transulfuration. Scriver C R, Beaudet A L, Sly W S, Valle D. The Metabolic Basis of Inherited Disease.
171. Frosst P, Blom H J, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. 10:1995;111-113.
172. Mandel H, Brenner B, Berant M. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. New England Journal of Medicine. 334:1996;763-768.
173. Welch G N, Loscalzo J. Homocysteine and atherothrombosis. New England Journal of Medicine. 338:1998;1042-1050.
174. Meijers J C, Tekelenburg W, Marquart J A. Factors XI levels: a new risk factor for thrombosis. Thrombosis and Haemostasis. 82:1999;496.
175. Ohlin A K, Marlar R A. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood. 85:1995;330-336.
176. Nakazawa F, Koyama T, Saito T. Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation. British Journal of Haematology. 106:1999;416-420.
177. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thrombosis and Haemostasis. 73:1995;151-161.